Just out., February 18, 2011, Page 7, Image 7

OREGON'S LGBTO N EW S M A G A ZIN E
FEBR U AR Y 18, 2011
* * L
e
***60047,
SS.^OOt
^ "7 7 7 ?
" ° UP*X4760
Car<l Holt
,ae,lO0Kxxx
Cla'ms Pro
C(
A?*'r
* >0»>onjl ^
'" ‘ " « « a ,,,
' /
Ä
You can save on KALETRA PLUS
your other HIV medications now!*
Get a KALETRA PLUS Card.
• Ask your doctor
• Call 1-877-220-3829 or
• Visit PositivePartnershipProgram.com
‘ Eligibility restrictions apply. See card for details. Medication coverage must
be part of your KALETRA-based regimen.
KALETRA is a prescription anti-H IV-1 medicine called a protease inhibitor that contains lopinavir and
ritonavir. KALETRA is used with other anti-H IV -1 medicines to increase the chance of treatm ent response
in people with human immunodeficiency virus (HIV-1) infection. It is not known if KALETRA is safe and
KALETRA Safety Considerations
,v . f i
‘v,
i U 2 ", I 4
...
'
-iS* •$.> * -it.
^
.......' K r
>•• -
.
■,
Do not take KALETRA if you are allergic to any of its ingredients, including lopinavir or ritonavir. Do not take
KALETRA with certain medicines, as they can cause serious problems, death, or make KALETRA less effective
against HIV. Some patients taking KALETRA can develop inflammation of the pancreas and liver problems,
which can cause death. Patients may develop changes in heart rhythm, large increases in triglycerides
and cholesterol, diabetes, high blood sugar, changes in body fat, and/or increased bleeding in people with
hemophilia. Some patients may develop signs and symptoms of serious infections they already have after
starting anti-HIV medicines. Please see Brief Sum m ary for more details.
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1-800-FDA-1088 (1-800-332-1088).
J-v -Ç " fi , '
% 4fc»
■ '. - jr* . •
: V, f
. i " T , if ’ 5*/,.
; , >**&!;» » ‘
If you cannot afford your medication, contact: www.pparx.org or call the toll-free
number (1-888-4PPA-N0W) or (1-888-477-2669) for assistance.
For additional information about KALETRA, call 1-866-KALETRA (1-866-525-3872)
or visit KALETRA.com.
'VijL.
.* m
V •
^ ' ■
**>. ■' -m&L
P le a s e se e B rief S u m m a ry on a d ja c e n t p a g e s .
.¿ 'v
•ffi *
for illustrative purposes only
I laboratori«. AW#" f's> >
August 2010 P» led m u:
'À7,
KALETRA
.
(lo p in a v i r/ri t o n a v i r)
Z_